Surprise market reaction: Shares rose over 2% despite net profit plunging more than 56% year-on-year in Q4 FY26, aided by better-than-feared underlying performance. Growth drivers: Biosimilars segment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results